[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368829-105":59,"doc-detail-368829-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","application-of-nanobody-based-car-t-in-tumor-immunotherapy-review","Application of Nanobody-Based CAR-T in Tumor Immunotherapy - Review","","Chimeric antigen receptor (CAR) T cell therapy is a cellular immunotherapy with strong clinical potential and high target specificity. CAR-T cells use membrane receptors to recognize antigens on cancer cells. The review outlines CAR architecture, including extracellular, transmembrane, and cytoplasmic domains. Nanobodies—camelid VHH-derived antibody fragments—provide small size, high affinity, adaptable functions, and stability, enabling laboratory-to-clinic translation with promising efficacy in hematologic and solid tumors.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/application-of-nanobody-based-car-t-in-tumor-immunotherapy-review/368829/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/application-of-nanobody-based-car-t-in-tumor-immunotherapy-review/368829.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is nanobody-based CAR-T and why is it considered promising?","Question",{"text":113,"@type":114},"Nanobody-based CAR-T uses nanobody fragments derived from camelid VHH as antigen-specific binding domains on engineered T cells. Their small size, high target affinity, and stability support effective tumor targeting with promising therapeutic efficacy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What structural components make up a CAR-T receptor?",{"text":118,"@type":114},"A CAR consists of three main elements: an extracellular antigen-binding domain, a transmembrane domain, and a cytoplasmic signaling domain that activates and enhances T-cell function after antigen binding.",{"name":120,"@type":111,"acceptedAnswer":121},"How do nanobodies differ from scFvs in CAR designs?",{"text":122,"@type":114},"Nanobodies are single-domain antibody fragments from camelids and can bind epitopes not always accessible to scFvs. They also avoid some folding/assembly limitations of scFvs and may show lower immunogenicity and good biocompatibility.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368829,1790210525,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},4398046744996,"INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE 56: 187, 2025  \nApplication of nanobody‑based CAR‑Tin tumor immunotherapy (Review)  \nHONGJING LIU 1 , XUEPING LIU 1 , XUYAN ZHOU2 , SILIANG dUAN3 , XIN HUANG 1 , HONGXIN FEI4 and YALI KOU 1  \n1  \ndepartment of Basic Medical Science, Guangxi Health Science college, Nanning, Guangxi Zhuang Autonomous Region 530023, 2  \nP.R. china; Department of Gastrointestinal and Anus Surgery, First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi Zhuang Autonomous Region 530023, P.R. china; 3department of Medicine, Guangxi University of Science and Technology, Liuzhou, Guangxi Zhuang Autonomous Region 545005, P.R. china;  \n4  \ndepartment of Basic Medical Science, Youjiang Medical University for Nationalities, Baise,  \nGuangxi Zhuang Autonomous Region 533000, P.R. china  \nReceived May 9, 2025; Accepted August 18, 2025  \ndOI: 10.3892/ijmm.2025.5628  \nAbstract. chimeric antigen receptor (cAR) T cell therapy is a type of cellular immunotherapy showing promising clinical effectiveness and high precision. cAR‑T cells express membrane receptors with high specificity, which enable them to identify certain target antigens generated by cancerous cells. The three primary structural elements of the cAR are the extracellular domain, transmembrane domain and cyto‑ plasmic domain. Nanobodies are a type of antibody fragment derived from the variable domains of camelid heavy chain antibodies (VHH), which are the antigen‑specific binding domains. They have high clinical applicability due to their tiny size, excellent target affinity, adaptable functions and guaranteed stability. Structurally pre‑designed nanobodies were transduced in primary T lymphocytes, forming cAR‑T cells and these have been demonstrated to have inhibitory effects on hematologic malignancy or solid tumor cells/tissues both in vivo and in vitro. At present, a number of novel nanobody‑based modalities can include a single nanobody, abi‑valent nanobody and multivalent nanobody cAR‑T cells with bispecific and multispecific characteristics, showing promising therapeutic efficacy that is similar to CAR‑T cells  \nCorrespondence to: Mrs. Yali Kou, department of Basic Medical Science, Guangxi Health Science college, 8 Kunlun Road, Nanning, Guangxi Zhuang Autonomous Region 530023, P.R. china  \nE‑mail: [13617811525@163.com](13617811525@163.com)  \ndr Hongxin Fei, department of Basic Medical Science, Youjiang Medical University for Nationalities, 128 Baise Road, Baise, Guangxi Zhuang Autonomous Region 533000, P.R. china  \nE‑mail: [feihongxin2008@163.com](feihongxin2008@163.com)  \nKey words: chimeric antigen receptor‑T cells, nanobody, camelid heavy chain antibodies, bispecific antibody, B‑cell maturation antigen  \nmodulated with a single‑chain variable fragment. Intriguingly, CAR‑T cells targeting the B‑cell maturation antigen modified using an anti‑B‑cell maturation antigen single nanobody or bivalent nanobody have been shown to exhibit clinical efficacy comparable to scFv‑modulated cAR‑T cells. The application of nanobodies in cAR‑T therapy has been well established from laboratory‑based evidence to clinical application and they have great potential for developing advanced cAR‑T cells for more complex employment.  \nContents  \n1. Introduction  \n2. development of cAR‑T  \n3. The antigen‑binding structure of cARs  \n4. Nanobody‑based cAR designs  \n5. Nanobodies in optimized cAR  \n6. Recent advances in various anti‑BcMA cAR‑T cells  \n7. challenges and mitigation strategies  \n8. conclusion  \n1. Introduction  \nImmune cellular therapy represents a large number of thera‑ peutic modalities used in immune‑oncology and that has been at the forefront of antitumor clinical strategies (1‑3) . chimeric antigen receptor (cAR) T cell therapy has demonstrated consistent therapeutic advances for the treatment of patients, although there are challenges in the latter that need to be overcome (4,5) . An illustration of clinical therapy employing cAR‑","cbCaitEl0rfc3Ymz","https://ap.wps.com/l/cbCaitEl0rfc3Ymz","pdf",2511008,"English","# Introduction\n## Development of CAR-T\n## The antigen-binding structure of CARs\n## Nanobody-based CAR designs\n## Nanobodies in optimized CAR\n## Recent advances in various anti-BCMA CAR-T cells\n## Challenges and mitigation strategies\n## Conclusion","[{\"question\":\"What is nanobody-based CAR-T and why is it considered promising?\",\"answer\":\"Nanobody-based CAR-T uses nanobody fragments derived from camelid VHH as antigen-specific binding domains on engineered T cells. Their small size, high target affinity, and stability support effective tumor targeting with promising therapeutic efficacy.\"},{\"question\":\"What structural components make up a CAR-T receptor?\",\"answer\":\"A CAR consists of three main elements: an extracellular antigen-binding domain, a transmembrane domain, and a cytoplasmic signaling domain that activates and enhances T-cell function after antigen binding.\"},{\"question\":\"How do nanobodies differ from scFvs in CAR designs?\",\"answer\":\"Nanobodies are single-domain antibody fragments from camelids and can bind epitopes not always accessible to scFvs. They also avoid some folding/assembly limitations of scFvs and may show lower immunogenicity and good biocompatibility.\"}]","Application of Nanobody-Based CAR-T in Tumor Immunotherapy - Review | PDF",1790178857,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/431ef5ebf3a8793868fce8ba5789c3ca.webp",983,1357,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a8dad8b6f69e36fd9412620a2c4134b.webp",982,1356,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8177d36090ca8321d55918400538559f.webp",981,1354,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0482b05abde5c34bc84958c8de83e94.webp",980,1353]